{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001645460","name":"Cue Biopharma, Inc.","summary":"Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing injectable therapeutics using its Immuno-STAT platform to selectively modulate disease-specific T cells. Key candidates include CUE-401 (autoimmune diseases, preclinical), CUE-501 (autoimmune B cell depletion, licensed to Boehringer Ingelheim), CUE-101 and CUE-102 (HPV+ cancers and WT1-expressing cancers, licensed to ImmunoScape). The platform targets autoimmune, inflammatory, and oncology indications by modulating regulatory and effector T cells.","people":[],"products":[{"name":"CUE-401","type":"platform","description":"Preclinical bifunctional fusion protein using TGF-beta and IL-2 to induce and expand regulatory T cells for autoimmune and inflammatory diseases."},{"name":"CUE-501","type":"platform","description":"Redirects anti-viral memory T cells to deplete pathogenic autoimmune B cells; licensed to Boehringer Ingelheim."},{"name":"CUE-101","type":"platform","description":"Selectively activates CD8+ T cells against HPV+ cancers; licensed to ImmunoScape Pte. Ltd."},{"name":"CUE-102","type":"platform","description":"Selectively activates CD8+ T cells against WT1-expressing cancers; licensed to ImmunoScape Pte. Ltd."},{"name":"Immuno-STAT Platform","type":"platform","description":"Modular, flexible biologics engineering framework for selective T cell modulation across autoimmune, inflammatory, and oncology indications."}],"partnerships":[{"partner_name":"Boehringer Ingelheim International GmbH","partnership_type":"licensing","description":"Collaboration and license agreement signed April 2025 for development of CUE-501 targeting autoimmune B cell depletion.","start_date":null},{"partner_name":"ImmunoScape Pte. Ltd.","partnership_type":"licensing","description":"Collaboration and license agreement for CUE-101 and CUE-102 oncology candidates to develop in vivo cell therapy for solid tumors.","start_date":null},{"partner_name":"Albert Einstein College of Medicine","partnership_type":"licensing","description":"Exclusive worldwide license for core T cell engineering platform patents, with royalties, milestones, and maintenance fees payable to Einstein.","start_date":null}],"affiliations":[],"origin":{"leaf":"6542a454004ede866183f8258c6960d6cd3042081cdac46d5d8281162629d870","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"ffe7b50570d188503daa006003d2e3ccbb0876fabd982d04ebdbc8fbeb660959","parent":"3d5a967a0931ca2704cb2eaf8c2fc980e60df9f6b05869ecff4f07d679beb9d2","source":"0001193125-26-108287","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":342,"hourly_limit":500,"remaining":158,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}